Efficacy and safety of apremilast in pediatric patients with moderate-to-severe plaque psoriasis: 16-week results from SPROUT, a randomized controlled trial
Loretta Fiorillo(University of Alberta), Lisa M. Arkin(University of Wisconsin–Madison), Rajneet K. Oberoi(Amgen (United States)), Emily Becker(Driscoll Children's Hospital), Zuoshun Zhang(Amgen (United States)), Anna Belloni Fortina(University of Padua), Peter Maes(Amgen (United States)), Susana Armesto(Marqués de Valdecilla University Hospital), Maria Paris(Amgen (United States)), R. de Lucas(Hospital Universitario La Paz), Wendy Zhang(Amgen (United States)), Boni E. Elewski(University of Alabama at Birmingham)
Cited by 28
Related Papers
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics
|Journal of the American Academy of Dermatology|2019|917
Cigarette Smoking, Body Mass Index, and Stressful Life Events as Risk Factors for Psoriasis: Results from an Italian Case–Control Study
|Journal of Investigative Dermatology|2005|644
Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities
|Journal of the American Academy of Dermatology|2019|484
Chilblain‐like lesions during COVID‐19 epidemic: a preliminary study on 63 patients
|Journal of the European Academy of Dermatology and Venereology|2020|248
Methotrexate treatment in juvenile localized scleroderma: A randomized, double-blind, placebo-controlled trial
|Arthritis & Rheumatism|2011|216